Your browser doesn't support javascript.
loading
Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin.
Miller, L L; Korn, E L; Stevens, D S; Janik, J E; Gause, B L; Kopp, W C; Holmlund, J T; Curti, B D; Sznol, M; Smith, J W; Urba, W J; Donegan, S E; Watson, T M; Longo, D L.
Affiliation
  • Miller LL; Frederick Cancer Research and Development Center, Biological Response Modifiers Program, National Cancer Institute, Frederick, MD, USA. langdon.l.miller@am.pnu.com
Blood ; 93(10): 3250-8, 1999 May 15.
Article in En | MEDLINE | ID: mdl-10233876
Search on Google
Database: MEDLINE Main subject: Carboplatin / Granulocyte-Macrophage Colony-Stimulating Factor / Interleukin-3 / Neoplasms Type of study: Clinical_trials Limits: Adult / Humans Language: En Journal: Blood Year: 1999 Type: Article Affiliation country: United States
Search on Google
Database: MEDLINE Main subject: Carboplatin / Granulocyte-Macrophage Colony-Stimulating Factor / Interleukin-3 / Neoplasms Type of study: Clinical_trials Limits: Adult / Humans Language: En Journal: Blood Year: 1999 Type: Article Affiliation country: United States